Novo Nordisk 's ( NVO +2.93%) shareholders must be happy to see 2025 finally come to a close. It was not a good year for the ...

With just about a week to go until 2026, Novo announced that its new weight loss pill under the brand name Wegovy had been ...

The U.S. Food and Drug Administration has approved Novo Nordisk’s Wegovy® pill, making it the first and only oral GLP-1 ...

Novo Nordisk’s oral Wegovy gets FDA approval, but rising costs and competition threaten profits. Learn why analysts rate NVO ...

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which has upheld the company's patent protection ...

Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine ...

Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup in the company's ...

Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Monday’s approval gives Novo Nordisk a win against GLP-1 competitor Eli Lilly, which manufactures a weight loss injectable ...

Omeros transitions from a distressed microcap to a small-cap following a transformative Novo Nordisk deal and FDA approval of ...